CY2013029PI2 - NEW INSULIN DERIVATIVES - Google Patents

NEW INSULIN DERIVATIVES

Info

Publication number: CY2013029PI2
Authority: CY; Cyprus
Prior art keywords: insulin derivatives; new insulin; new; derivatives; insulin
Prior art date: 2003-08-05

Application number

CY2013029C

Other languages

Greek (el)

Original Assignee

Novo Nordisk A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-05

Filing date

2013-07-08

Publication date

2015-11-04

2013-07-08 Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S

2015-11-04 Publication of CY2013029PI1 publication Critical patent/CY2013029PI1/en

2015-11-04 Publication of CY2013029PI2 publication Critical patent/CY2013029PI2/en

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Toxicology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

CY2013029C 2003-08-05 2013-07-08 NEW INSULIN DERIVATIVES CY2013029PI2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA200301129		2003-08-05
US49545103P	2003-08-14	2003-08-14
EP04739008A EP1660531A2 (en)	2003-08-05	2004-07-22	Novel insulin derivatives

Publications (2)

Publication Number	Publication Date
CY2013029PI1 CY2013029PI1 (en)	2015-11-04
CY2013029PI2 true CY2013029PI2 (en)	2015-11-04

Family

ID=34117520

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
CY20131100259T CY1113850T1 (en)	2003-08-05	2013-03-28	NEW INSULIN PRODUCERS
CY2013027C CY2013027PI2 (en)	2003-08-05	2013-07-04	NEW INSULIN DERIVATIVES
CY2013029C CY2013029PI2 (en)	2003-08-05	2013-07-08	NEW INSULIN DERIVATIVES
CY2013029C CY2013029I2 (en)	2003-08-05	2023-12-28	NEW INSULIN DERIVATIVES
CY2013027C CY2013027I2 (en)	2003-08-05	2024-01-31	NEW INSULIN DERIVATIVES

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
CY20131100259T CY1113850T1 (en)	2003-08-05	2013-03-28	NEW INSULIN PRODUCERS
CY2013027C CY2013027PI2 (en)	2003-08-05	2013-07-04	NEW INSULIN DERIVATIVES

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
CY2013029C CY2013029I2 (en)	2003-08-05	2023-12-28	NEW INSULIN DERIVATIVES
CY2013027C CY2013027I2 (en)	2003-08-05	2024-01-31	NEW INSULIN DERIVATIVES

Country Status (18)

Country	Link
US (3)	US7615532B2 (en)
EP (3)	EP2107069B1 (en)
JP (1)	JP4463814B2 (en)
KR (1)	KR101159559B1 (en)
AU (2)	AU2004261353B2 (en)
BE (2)	BE2013C035I2 (en)
BR (1)	BRPI0413276B8 (en)
CA (1)	CA2531988C (en)
CY (5)	CY1113850T1 (en)
FR (2)	FR13C0035I2 (en)
HU (1)	HUS1300033I1 (en)
IL (1)	IL172980A (en)
LU (2)	LU92213I2 (en)
MX (1)	MXPA06001283A (en)
NO (5)	NO340925B1 (en)
PL (1)	PL2107069T3 (en)
RU (1)	RU2518460C2 (en)
WO (1)	WO2005012347A2 (en)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005012346A1 (en) *	2003-07-25	2005-02-10	Conjuchem, Inc.	Long lasting insulin derivatives and methods thereof
JP4463814B2 (en)	2003-08-05	2010-05-19	ノボノルディスクアクティーゼルスカブ	New insulin derivatives
EP1846446B1 (en)	2005-02-02	2013-06-26	Novo Nordisk A/S	Insulin derivatives
WO2006082205A1 (en) *	2005-02-02	2006-08-10	Novo Nordisk A/S	Insulin derivatives
JP4808785B2 (en) *	2005-12-28	2011-11-02	ノボ・ノルデイスク・エー／エス	Insulin composition and method for producing the composition
ES2387955T3 (en) *	2006-02-27	2012-10-04	Novo Nordisk A/S	Insulin derivatives
WO2007104736A2 (en) *	2006-03-13	2007-09-20	Novo Nordisk A/S	Acylated single chain insulin
EP2015722B1 (en)	2006-04-28	2016-11-16	Avent, Inc.	Antimicrobial site dressings
EP2386572B1 (en) *	2006-05-09	2015-07-08	Novo Nordisk A/S	Insulin derivative
JP5269766B2 (en) *	2006-05-09	2013-08-21	ノボ・ノルデイスク・エー／エス	Insulin derivative
CN101437849B (en) *	2006-05-09	2015-09-30	诺沃-诺迪斯克有限公司	Insulin derivatives
JP5097900B2 (en) *	2006-06-27	2012-12-12	独立行政法人物質・材料研究機構	Method for producing active ester of organic acid or derivative thereof
EP2049149B1 (en)	2006-07-31	2015-04-15	Novo Nordisk A/S	Pegylated extended insulins
JP5864834B2 (en)	2006-09-22	2016-02-17	ノボ・ノルデイスク・エー／エス	Protease resistant insulin analogue
ES2563038T3 (en)	2007-04-30	2016-03-10	Novo Nordisk A/S	Method for drying a protein composition, a dry protein composition and a pharmaceutical composition comprising the dry protein
WO2008145732A1 (en) *	2007-06-01	2008-12-04	Novo Nordisk A/S	Stable non-aqueous pharmaceutical compositions
EP2164466A1 (en)	2007-06-01	2010-03-24	Novo Nordisk A/S	Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
EP2167032B1 (en)	2007-06-13	2019-08-07	Novo Nordisk A/S	Pharmaceutical formulation comprising an insulin derivative
JP5730569B2 (en) *	2007-08-15	2015-06-10	ノボ・ノルデイスク・エー／エス	Insulin analogues having acyl and alkylene glycol moieties
JP5721432B2 (en)	2007-08-15	2015-05-20	ノボ・ノルデイスク・エー／エス	Insulin having an acyl moiety containing an amino acid-containing alkylene glycol repeating unit
CN101157725B (en) *	2007-10-24	2012-07-25	中国药科大学	Preparation method of human insulin analogue and usage thereof
ES2543393T3 (en) *	2007-11-08	2015-08-18	Novo Nordisk A/S	Insulin derivative
WO2009063072A2 (en)	2007-11-16	2009-05-22	Novo Nordisk A/S	Pharmaceutical compositions containing insulin and an insulinotropic peptide
US9260502B2 (en)	2008-03-14	2016-02-16	Novo Nordisk A/S	Protease-stabilized insulin analogues
CN102037008B (en)	2008-03-18	2016-08-31	诺沃-诺迪斯克有限公司	Protease-stabilized, acylated insulin analogs
JP5591243B2 (en)	2008-09-12	2014-09-17	ノボ・ノルデイスク・エー／エス	Method for acylating peptides or proteins
CA2738615A1 (en) *	2008-10-30	2010-05-06	Novo Nordisk A/S	Treating diabetes melitus using insulin injections with less than daily injection frequency
JP5599822B2 (en)	2009-01-23	2014-10-01	ノヴォノルディスクアー／エス	FGF21 derivatives having albumin binder ABCDE and their use
EP2493919A1 (en)	2009-10-30	2012-09-05	Novo Nordisk A/S	Derivatives of cgrp
JP5908847B2 (en)	2010-01-12	2016-04-26	ノヴォノルディスクアー／エス	Pharmaceutical composition for oral administration of insulin peptides
WO2011101277A1 (en)	2010-02-16	2011-08-25	Novo Nordisk A/S	Conjugated proteins
EP2536434B1 (en)	2010-02-16	2016-04-20	Novo Nordisk A/S	Purification method
AU2011252127B2 (en)	2010-05-10	2014-02-20	Novo Nordisk A/S	Process for the preparation of insulin-zinc complexes
US20130345397A1 (en)	2010-05-25	2013-12-26	Andrea Robinson	Methods for the synthesis of dicarba bridges in peptides
JP6013330B2 (en)	2010-06-23	2016-10-25	ノヴォノルディスクアー／エス	Human insulin containing additional disulfide bonds
CN102947331B (en)	2010-06-23	2016-08-03	诺沃—诺迪斯克有限公司	Comprise the insulin analog of extra disulfide bond
EP2585485A1 (en) *	2010-06-23	2013-05-01	Novo Nordisk A/S	Insulin derivatives containing additional disulfide bonds
JP2013540771A (en)	2010-10-15	2013-11-07	ノヴォノルディスクアー／エス	Novel N-terminally modified insulin derivative
JP6049625B2 (en) *	2010-10-27	2016-12-21	ノヴォノルディスクアー／エス	Treatment of diabetes mellitus using insulin injections given at various injection intervals
US20130261051A1 (en)	2010-10-27	2013-10-03	Thue Johansen	Treating Diabetes Melitus Using Insulin Injections Administered With Varying Injection Intervals
WO2012080320A1 (en)	2010-12-14	2012-06-21	Novo Nordisk A/S	Fast-acting insulin in combination with long-acting insulin
WO2012110422A1 (en)	2011-02-15	2012-08-23	Novo Nordisk A/S	Long-acting il-1 receptor antagonists
EP2691108A1 (en) *	2011-03-28	2014-02-05	Novo Nordisk A/S	Novel glucagon analogues
US20140056953A1 (en)	2011-04-14	2014-02-27	Novo Nordisk A/S	Fatty acid acylated amino acids for oral peptide delivery
US9260503B2 (en)	2011-06-15	2016-02-16	Novo Nordisk A/S	Multi-substituted insulins
AR088161A1 (en)	2011-09-23	2014-05-14	Novo Nordisk As	GLUCAGON ANALOGS
KR20140104994A (en) *	2011-12-15	2014-08-29	샹하이 헨그루이 파마수티컬 컴퍼니 리미티드	Human Insulin Analogue and Acylated Derivative thereof
JP2015502971A (en)	2011-12-21	2015-01-29	ノヴォノルディスクアー／エス	N-terminal modified insulin derivative
CA2870313A1 (en)	2012-04-11	2013-10-17	Novo Nordisk A/S	Insulin formulations
US20160031962A1 (en) *	2012-04-20	2016-02-04	Kleomenis K. Barlos	Solid phase peptide synthesis of insulin using side chain achored lysine
MX363119B (en)	2012-05-01	2019-03-11	Novo Nordisk As	Pharmaceutical composition.
US20150111820A1 (en)	2012-07-09	2015-04-23	Novo Nordisk A/S	Novel use of insulin derivatives
UA116217C2 (en)	2012-10-09	2018-02-26	Санофі	Exendin-4 derivatives as dual glp1/glucagon agonists
EP2908846A1 (en)	2012-10-17	2015-08-26	Novo Nordisk A/S	Fatty acid acylated d-amino acids for oral peptide delivery
AR099912A1 (en)	2012-12-21	2016-08-31	Sanofi Sa	DERIVATIVES OF EXENDINA-4 AS DOUBLE AGONISTS OF GLP1 / GIP OR TRIPLES OF GLP1 / GIP / GLUCAGON
US20160296602A1 (en) *	2013-03-20	2016-10-13	Novo Nordisk A/S	Dosing Regimen
AU2014255608B2 (en)	2013-04-18	2018-01-25	Novo Nordisk A/S	Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
WO2014177623A1 (en)	2013-04-30	2014-11-06	Novo Nordisk A/S	Novel administration regime
GB201315335D0 (en)	2013-08-29	2013-10-09	Of Singapore	Amino diacids containing peptide modifiers
HUE036702T2 (en)	2013-10-07	2018-07-30	Novo Nordisk As	Novel derivative of an insulin analogue
FR3013049B1 (en)	2013-11-14	2015-11-13	You-Ping Chan	ANALOGUE OF INSULIN GLARGINE
TW201609797A (en)	2013-12-13	2016-03-16	賽諾菲公司	Dual GLP-1/glucagon receptor agonists
EP3080150B1 (en)	2013-12-13	2018-08-01	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609796A (en)	2013-12-13	2016-03-16	賽諾菲公司	Non-acylated EXENDIN-4 peptide analogues
WO2015086729A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/gip receptor agonists
EP3107560A1 (en)	2014-02-18	2016-12-28	Novo Nordisk A/S	Stable glucagon analogues and use for treatment of hypoglycaemia
AR099569A1 (en)	2014-02-28	2016-08-03	Novo Nordisk As	INSULIN DERIVATIVES AND THE MEDICAL USES OF THESE
TW201625668A (en)	2014-04-07	2016-07-16	賽諾菲公司	Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625669A (en)	2014-04-07	2016-07-16	賽諾菲公司	Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625670A (en)	2014-04-07	2016-07-16	賽諾菲公司	Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
US10570184B2 (en)	2014-06-04	2020-02-25	Novo Nordisk A/S	GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (en)	2015-06-05	2017-09-27	Sanofi Sa	PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
TW201706291A (en)	2015-07-10	2017-02-16	賽諾菲公司	New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
WO2017032797A1 (en)	2015-08-25	2017-03-02	Novo Nordisk A/S	Novel insulin derivatives and the medical uses hereof
EP3341401A1 (en)	2015-08-25	2018-07-04	Novo Nordisk A/S	Novel insulin derivatives and the medical uses hereof
JP7432361B2 (en) *	2016-08-02	2024-02-16	江蘇恒瑞医薬股▲ふん▼有限公司	Acylated derivatives of human insulin or its analogs
WO2018096164A1 (en)	2016-11-28	2018-05-31	Novo Nordisk A/S	Insulin degludec for treating diabetes
JP7193455B2 (en)	2016-11-28	2022-12-20	ノヴォノルディスクアー／エス	Insulin degludec in cardiovascular conditions
CN110099719A (en)	2016-11-28	2019-08-06	诺和诺德股份有限公司	For improving glycemic control and reducing acute and long term diabetes complications moral paddy insulin
HUE055231T2 (en)	2016-12-16	2021-11-29	Novo Nordisk As	Insulin-containing pharmaceutical preparations
JOP20190273A1 (en) *	2017-05-26	2019-11-24	Lilly Co Eli	Insulin treated with basil complex
MX2020007929A (en)	2018-02-09	2020-10-01	Jiangsu Hengrui Medicine Co	Codon optimized precursor gene and signal peptide gene of human insulin analogue.
KR20210016400A (en)	2018-05-24	2021-02-15	지앙수 헨그루이 메디슨 컴퍼니 리미티드	Method for producing a precursor of recombinant human insulin or its analog
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
JP7410891B2 (en)	2018-06-26	2024-01-10	ノボ・ノルデイスク・エー／エス	System providing dosing recommendations for basal insulin titration
KR102666154B1 (en)	2018-08-08	2024-05-20	주식회사 대웅제약	Long-acting Insulin Analog and Derivatives Thereof
KR20200080748A (en)	2018-12-27	2020-07-07	주식회사 폴루스	A Method for Purifying Proinsulin Using Anion Exchange Chromatography
KR20200080747A (en)	2018-12-27	2020-07-07	주식회사 폴루스	An Enzymatic Conversion Composition for Producing Insulin from Proinsulin and a Method for Producing Insulin from Proinsulin Using the Same
JP7518149B2 (en)	2019-07-12	2024-07-17	ノヴォノルディスクアー／エス	High-concentration insulin preparations
TW202434620A (en)	2019-07-31	2024-09-01	美商美國禮來大藥廠	Relaxin analogs and methods of using the same
BR112022013150A2 (en)	2019-12-30	2023-02-28	Gan & Lee Pharmaceuticals Co Ltd	INSULIN DERIVATIVE
CN115867308A (en)	2020-05-15	2023-03-28	伊莱利利公司	Delayed acting acylated insulin compounds
CN113773398B (en) *	2020-06-10	2023-05-23	宁波鲲鹏生物科技有限公司	De-glu insulin derivative and application thereof
EP4180060A1 (en)	2021-11-15	2023-05-17	Adocia	Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en)	2022-06-30	2024-01-03	Adocia	Solid compositions comprising a peptide or a protein and an acylated amino acid
US20250000948A1 (en)	2021-11-15	2025-01-02	Adocia	Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4471053A1 (en)	2022-01-28	2024-12-04	Gan & Lee Pharmaceuticals Co., Ltd.	Acylated insulin
EP4299071A1 (en)	2022-07-01	2024-01-03	Adocia	Compositions comprising a peptide or a protein and an acylated amino acid
WO2025104600A1 (en) *	2023-11-15	2025-05-22	Ambio, Inc.	Insulin analogs for the treatment of human metabolic disorder and disease

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1212679B (en)	1957-08-03	1966-03-17	Novo Terapeutisk Labor As	Process for the preparation of insulin solutions
GB1042194A (en)	1962-04-30	1966-09-14	Olin Mathieson	Insulin preparations
US3528960A (en)	1968-10-07	1970-09-15	Lilly Co Eli	N-carboxyaroyl insulins
US3868358A (en) *	1971-04-30	1975-02-25	Lilly Co Eli	Protamine-insulin product
GB1492997A (en)	1976-07-21	1977-11-23	Nat Res Dev	Insulin derivatives
JPS5767548A (en)	1980-10-14	1982-04-24	Shionogi & Co Ltd	Insulin analog and its preparation
FI78616C (en) *	1982-02-05	1989-09-11	Novo Industri As	Process for preparing an infused stabilized insulin solution having an elevated zinc content
PH25772A (en)	1985-08-30	1991-10-18	Novo Industri As	Insulin analogues, process for their preparation
NZ222907A (en)	1986-12-16	1990-08-28	Novo Industri As	Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5605884A (en) *	1987-10-29	1997-02-25	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Factor VIII formulations in high ionic strength media
US4877608A (en)	1987-11-09	1989-10-31	Rorer Pharmaceutical Corporation	Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (en)	1988-04-05	1989-10-11	Kodama Kk	Insulin derivative and use thereof
DE3827533A1 (en) *	1988-08-13	1990-02-15	Hoechst Ag	PHARMACEUTICAL PREPARATION FOR TREATING THE DIABETES MELLITUS
JPH04502465A (en)	1988-12-23	1992-05-07	ノボ　ノルディスク　アクティーゼルスカブ	human insulin analogue
IL93282A (en)	1989-02-09	1995-08-31	Lilly Co Eli	Insulin analogs
IT1240314B (en)	1989-09-28	1993-12-07	Immunobiology Research Institutes, Inc.	STABILIZED AQUEOUS FORMULATIONS OF SMALL PEPTIDES.
EP0506792B1 (en) *	1989-12-21	1995-05-17	Novo Nordisk A/S	Insulin preparations containing nicotinic acid or nicotinamide
DK45590D0 (en)	1990-02-21	1990-02-21	Novo Nordisk As
JP3193398B2 (en)	1991-07-23	2001-07-30	サンデン株式会社	Showcase
AU667503B2 (en)	1991-12-20	1996-03-28	Novo Nordisk Health Care Ag	A stabilized pharmaceutical formulation comprising growth hormone and histidine
US6869930B1 (en) *	1993-09-17	2005-03-22	Novo Nordisk A/S	Acylated insulin
HU217684B (en) *	1993-09-17	2000-03-28	Novo Nordisk A/S	Acylated insulin derivatives and pharmaceutical compositions containing them and their preparation
US6011007A (en) *	1993-09-17	2000-01-04	Novo Nordisk A/S	Acylated insulin
US5652216A (en)	1994-05-26	1997-07-29	Novo Nordisk A/S	Pharmaceutical preparation
AU3562195A (en)	1994-10-04	1996-04-26	Novo Nordisk A/S	Preparations containing aspb28 human insulin and nicotinamide
US5646242A (en)	1994-11-17	1997-07-08	Eli Lilly And Company	Selective acylation of epsilon-amino groups
US5830999A (en) *	1995-01-26	1998-11-03	Regents Of The University Of California	Stabilization of insulin through ligand binding interations
EP0871665B1 (en)	1995-03-17	2003-07-23	Novo Nordisk A/S	Insulin derivatives
US6251856B1 (en) *	1995-03-17	2001-06-26	Novo Nordisk A/S	Insulin derivatives
DK2275119T3 (en)	1995-07-27	2013-11-11	Genentech Inc	Stable, isotonic lyophilized protein formulation
US6451970B1 (en) *	1996-02-21	2002-09-17	Novo Nordisk A/S	Peptide derivatives
US5898267A (en) *	1996-04-10	1999-04-27	Mcdermott; Kevin	Parabolic axial lighting device
US5866538A (en) *	1996-06-20	1999-02-02	Novo Nordisk A/S	Insulin preparations containing NaCl
EP0938502B1 (en) *	1996-07-11	2004-10-06	Novo Nordisk A/S	Selective acylation method
US5905140A (en) *	1996-07-11	1999-05-18	Novo Nordisk A/S, Novo Alle	Selective acylation method
US5763401A (en)	1996-07-12	1998-06-09	Bayer Corporation	Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
PT821006E (en) *	1996-07-26	2004-09-30	Aventis Pharma Gmbh	INSULIN DERIVATIVES WITH ENHANCED ZINC LINK
IL119029A0 (en) *	1996-08-07	1996-11-14	Yeda Res & Dev	Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) *	1997-02-07	1999-04-27	Novo Nordisk A/S	Crystallization of proteins
AU742591B2 (en) *	1997-03-20	2002-01-10	Novo Nordisk A/S	Zinc free insulin crystals for use in pulmonary compositions
AU6611998A (en)	1997-03-20	1998-10-20	Novo Nordisk A/S	Therapeutic powder formulation for pulmonary administration, containing crystalline insulin
ATE220555T1 (en)	1997-03-20	2002-08-15	Novo Nordisk As	METHOD FOR PRODUCING A THERAPEUTIC POWDER BY COPRECIPITATION OF INSULIN AND AN ABSORPTION ENHANCER
US7097845B2 (en)	1997-04-23	2006-08-29	Jacob Sten Petersen	Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
DK1283051T3 (en)	1997-06-13	2006-10-16	Lilly Co Eli	Stable insulin formulations
US6451762B1 (en) *	1997-10-24	2002-09-17	Novo Nordisk A/S	Aggregates of human insulin derivatives
CA2306905A1 (en)	1997-10-24	1999-05-06	Eli Lilly And Company	Fatty acid-acylated insulin analogs
US20020155994A1 (en) *	1997-10-24	2002-10-24	Svend Havelund	Aggregates of human insulin derivatives
PL195845B1 (en) *	1997-10-24	2007-10-31	Novo Nordisk As	Aggregates of human insulin derivatives
ZA989744B (en)	1997-10-31	2000-04-26	Lilly Co Eli	Method for administering acylated insulin.
US6531448B1 (en) *	1997-12-23	2003-03-11	Eli Lilly And Company	Insoluble compositions for controlling blood glucose
JP2002500196A (en) *	1998-01-09	2002-01-08	ノヴォノルディスクアクティーゼルスカブ	Stabilized insulin composition
US6211144B1 (en) *	1998-10-16	2001-04-03	Novo Nordisk A/S	Stable concentrated insulin preparations for pulmonary delivery
CA2346969A1 (en)	1998-10-16	2000-04-27	Novo Nordisk A/S	Stable concentrated insulin preparations for pulmonary delivery
EP2193809B1 (en) *	1999-02-22	2015-04-08	University of Connecticut	Albumin-free factor VIII formulations
WO2000064940A1 (en)	1999-04-27	2000-11-02	Eli Lilly And Company	Insulin crystals for pulmonary administration
GB9930882D0 (en)	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
DE10022092A1 (en)	2000-05-08	2001-11-15	Aventis Behring Gmbh	Stabilized protein preparation and process for its preparation
US6652886B2 (en) *	2001-02-16	2003-11-25	Expression Genetics	Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (en)	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinc-free and low-zinc insulin preparations with improved stability
PT1412384E (en)	2001-06-28	2008-03-28	Novo Nordisk As	Stable formulation of modified glp-1
BR0215029A (en)	2001-12-20	2005-12-20	Lilly Co Eli	Insulin molecule, use of it, composition, use of it, microcrystalline, process for preparing it, use of it, and methods for preparing an insulin molecule, for treating hyperglycemia, and for treating diabetes mellitus
US8003605B2 (en) *	2002-03-13	2011-08-23	Novo Nordisk A/S	Minimising body weight gain in insulin treatment
ES2360182T3 (en) *	2002-05-07	2011-06-01	Novo Nordisk A/S	SOLUBLE FORMULATIONS THAT INCLUDE MONOMERIC INSULIN AND ACILATED INSULIN.
US20050232899A1 (en) *	2002-05-31	2005-10-20	Aradigm Corporation	Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en) *	2002-06-20	2004-01-01	Bruce Kerwin	Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (en)	2002-08-23	2006-08-25	(주)헬릭서	Health food comprising the extract of Actinidia arguta and related species for the prevention and improvement of allergic disease and non-allergic inflammatory disease
JP2006504772A (en)	2002-10-29	2006-02-09	アルザ・コーポレーション	Stabilized solid polypeptide particles
US20040138099A1 (en) *	2002-11-29	2004-07-15	Draeger Eberhard Kurt	Insulin administration regimens for the treatment of subjects with diabetes
WO2004069259A1 (en)	2003-02-07	2004-08-19	Ajinomoto Co., Inc.	Remedy for diabetes
BRPI0407680A (en)	2003-02-19	2006-03-01	Novartis Ag	methods for cancer diagnosis and cancer cell metastasis reduction
KR20060015469A (en)	2003-03-04	2006-02-17	더 테크놀로지 디벨로프먼트 컴퍼니 리미티드	Oral insulin composition, preparation method thereof and method of use
ES2382157T3 (en)	2003-06-25	2012-06-05	Novo Nordisk Health Care Ag	Liquid composition of factor VII polypeptides
US20050054818A1 (en) *	2003-07-02	2005-03-10	Brader Mark Laurence	Crystalline compositions for controlling blood glucose
JP4463814B2 (en)	2003-08-05	2010-05-19	ノボノルディスクアクティーゼルスカブ	New insulin derivatives
RU2352581C2 (en)	2003-08-05	2009-04-20	Ново Нордиск А/С	Insulin derivatives
BRPI0413518A (en)	2003-08-14	2006-10-10	Novo Nordisk Healthcare Ag	aqueous liquid pharmaceutical composition, method for preparing and using same, method for treating a factor responsive syndrome vii, and, airtight container
WO2005021022A2 (en)	2003-09-01	2005-03-10	Novo Nordisk A/S	Stable formulations of peptides
ES2229931B1 (en) *	2003-10-03	2006-01-16	Grifols, S.A.	BILOGICALLY STABLE LIQUID COMPOSITION OF FVIII, FVW OR HUMAN FVIII / FVW COMPLEX.
JP2007532096A (en) *	2003-11-14	2007-11-15	ノボ　ノルディスク　アクティーゼルスカブ	Method for producing acylated insulin
CA2551510C (en)	2003-12-23	2013-07-30	Pharmacia Corporation	Stable growth hormone liquid formulation
PT1740154E (en)	2004-03-12	2009-09-11	Biodel Inc	Insulin compositions with improved absorption
EA012281B1 (en)	2004-06-01	2009-08-28	Арес Трейдинг С.А.	Method of stabilizing proteins
JP4971160B2 (en)	2004-08-12	2012-07-11	シェーリングコーポレイション	Stable PEGylated interferon formulation
BRPI0514411B8 (en)	2004-08-17	2021-05-25	Regeneron Pharma	formulation, and, method of producing a formulation
EP1814581B1 (en)	2004-11-12	2016-03-16	Novo Nordisk A/S	Stable formulations of peptides comprising an acylated glp-1 analogue and a basal insuline
JP4874989B2 (en)	2004-11-22	2012-02-15	ノヴォノルディスクアー／エス	Soluble and stable insulin-containing formulation
US20060188555A1 (en)	2005-01-21	2006-08-24	Micheal Cormier	Therapeutic peptide formulations with improved stability
EP1846446B1 (en) *	2005-02-02	2013-06-26	Novo Nordisk A/S	Insulin derivatives
JP4808785B2 (en)	2005-12-28	2011-11-02	ノボ・ノルデイスク・エー／エス	Insulin composition and method for producing the composition
ES2387955T3 (en) *	2006-02-27	2012-10-04	Novo Nordisk A/S	Insulin derivatives
US7718609B2 (en)	2006-04-12	2010-05-18	Biodel Inc.	Rapid acting and long acting insulin combination formulations
EP2386572B1 (en) *	2006-05-09	2015-07-08	Novo Nordisk A/S	Insulin derivative
EP2167032B1 (en) *	2007-06-13	2019-08-07	Novo Nordisk A/S	Pharmaceutical formulation comprising an insulin derivative
WO2009063072A2 (en) *	2007-11-16	2009-05-22	Novo Nordisk A/S	Pharmaceutical compositions containing insulin and an insulinotropic peptide
TWI451876B (en) *	2008-06-13	2014-09-11	Lilly Co Eli	Pegylated insulin lispro compounds

2004
- 2004-07-22 JP JP2006522233A patent/JP4463814B2/en not_active Expired - Lifetime
- 2004-07-22 PL PL09165072T patent/PL2107069T3/en unknown
- 2004-07-22 CA CA2531988A patent/CA2531988C/en not_active Expired - Fee Related
- 2004-07-22 EP EP09165072A patent/EP2107069B1/en not_active Expired - Lifetime
- 2004-07-22 EP EP04739008A patent/EP1660531A2/en not_active Withdrawn
- 2004-07-22 KR KR1020067002551A patent/KR101159559B1/en not_active Expired - Lifetime
- 2004-07-22 WO PCT/DK2004/000511 patent/WO2005012347A2/en not_active Ceased
- 2004-07-22 AU AU2004261353A patent/AU2004261353B2/en active Active
- 2004-07-22 BR BRPI0413276A patent/BRPI0413276B8/en active IP Right Grant
- 2004-07-22 EP EP10174490.2A patent/EP2264065B1/en not_active Expired - Lifetime
- 2004-07-22 MX MXPA06001283A patent/MXPA06001283A/en active IP Right Grant
2006
- 2006-01-05 IL IL172980A patent/IL172980A/en active Protection Beyond IP Right Term
- 2006-01-30 US US11/343,005 patent/US7615532B2/en active Active
- 2006-03-02 NO NO20061026A patent/NO340925B1/en active Protection Beyond IP Right Term
2008
- 2008-12-29 RU RU2008152033/04A patent/RU2518460C2/en active
2009
- 2009-09-16 US US12/560,833 patent/US8828923B2/en not_active Expired - Lifetime
2010
- 2010-02-10 AU AU2010200497A patent/AU2010200497B2/en active Active
2013
- 2013-03-28 CY CY20131100259T patent/CY1113850T1/en unknown
- 2013-06-10 LU LU92213C patent/LU92213I2/en unknown
- 2013-06-11 BE BE2013C035C patent/BE2013C035I2/fr unknown
- 2013-06-19 BE BE2013C038C patent/BE2013C038I2/fr unknown
- 2013-06-19 LU LU92226C patent/LU92226I2/en unknown
- 2013-07-04 FR FR13C0035C patent/FR13C0035I2/en active Active
- 2013-07-04 CY CY2013027C patent/CY2013027PI2/en unknown
- 2013-07-05 FR FR13C0038C patent/FR13C0038I1/en active Active
- 2013-07-08 CY CY2013029C patent/CY2013029PI2/en unknown
- 2013-07-18 HU HUS1300033C patent/HUS1300033I1/en unknown
2014
- 2014-08-06 US US14/453,276 patent/US20140349925A1/en not_active Abandoned
2018
- 2018-01-11 NO NO2018002C patent/NO2018002I2/en unknown
- 2018-01-11 NO NO2018003C patent/NO2018003I1/en unknown
2023
- 2023-12-28 CY CY2013029C patent/CY2013029I2/en unknown
2024
- 2024-01-16 NO NO2024003C patent/NO2024003I1/en unknown
- 2024-01-16 NO NO2024004C patent/NO2024004I1/en unknown
- 2024-01-31 CY CY2013027C patent/CY2013027I2/en unknown

Also Published As

Publication number	Publication date
NO2018003I1 (en)	2018-01-11
CY2013029PI1 (en)	2015-11-04
CY2013029I2 (en)	2024-09-20
NO340925B1 (en)	2017-07-17
CY2013027PI1 (en)	2015-11-04
CA2531988C (en)	2016-06-28
EP2107069B1 (en)	2013-01-16
LU92213I2 (en)	2013-08-23
FR13C0035I1 (en)	2013-08-09
MXPA06001283A (en)	2006-04-11
WO2005012347A2 (en)	2005-02-10
LU92213I9 (en)	2018-11-19
CY2013027I1 (en)	2024-09-20
FR13C0038I1 (en)	2013-08-09
BE2013C038I2 (en)	2023-12-14
EP2107069A3 (en)	2009-11-25
AU2010200497A1 (en)	2010-03-04
NO2024004I1 (en)	2024-01-16
BE2013C035I2 (en)	2023-12-14
EP2264065A2 (en)	2010-12-22
LU92226I2 (en)	2015-04-29
KR101159559B1 (en)	2012-06-26
US20100009899A1 (en)	2010-01-14
EP2107069A2 (en)	2009-10-07
US20140349925A1 (en)	2014-11-27
IL172980A0 (en)	2006-06-11
EP1660531A2 (en)	2006-05-31
EP2264065B1 (en)	2017-03-08
LU92226I9 (en)	2018-11-19
US20060183668A1 (en)	2006-08-17
BRPI0413276A (en)	2006-10-10
JP2007523881A (en)	2007-08-23
KR20060132543A (en)	2006-12-21
RU2518460C2 (en)	2014-06-10
AU2010200497B2 (en)	2014-10-23
CY2013027I2 (en)	2024-09-20
FR13C0035I2 (en)	2014-03-07
BRPI0413276B1 (en)	2020-03-03
CA2531988A1 (en)	2005-02-10
CY2013029I1 (en)	2024-09-20
JP4463814B2 (en)	2010-05-19
AU2004261353B2 (en)	2009-12-10
AU2004261353A1 (en)	2005-02-10
NO20061026L (en)	2006-03-02
US7615532B2 (en)	2009-11-10
RU2008152033A (en)	2010-07-10
WO2005012347A3 (en)	2005-04-14
US8828923B2 (en)	2014-09-09
EP2264065A3 (en)	2011-07-27
HUS1300033I1 (en)	2016-08-29
CY2013027PI2 (en)	2015-11-04
NO2024003I1 (en)	2024-01-16
PL2107069T3 (en)	2013-06-28
BRPI0413276B8 (en)	2021-05-25
NO2018002I1 (en)	2018-01-11
NO2018002I2 (en)	2018-08-20
IL172980A (en)	2013-10-31
CY1113850T1 (en)	2015-11-04

Publication	Publication Date	Title
CY2013027I1 (en)	2024-09-20	NEW INSULIN DERIVATIVES
ATE340782T1 (en)	2006-10-15	PIPERIDINEBENZENESULFONAMIDE DERIVATIVES
CY2015036I1 (en)	2016-06-22	NEW OXAZOLIDINONE DERIVATIVES
ATE420066T1 (en)	2009-01-15	AMIDOACETONITRIL DERIVATIVES
ATE352550T1 (en)	2007-02-15	CHINAZOLINE DERIVATIVES
DK2609947T3 (en)	2020-07-06	Plaster-like infusion set
IS8108A (en)	2005-10-31	New compounds
DE602004017700D1 (en)	2008-12-24	TRANSMUKOSEN ADMINISTRATION
DK1606277T3 (en)	2008-08-18	Imidazol-4-yl-ethynyl-pyridine derivatives
IS2656B (en)	2010-08-15	New besimidasol derivatives
DK2107069T3 (en)	2013-04-15	New insulin derivatives
EP1661594A4 (en)	2010-04-14	SYRINGE
DE602004019555D1 (en)	2009-04-02	HETEROCYCLIC 7-AMINOALKYLIDENYLCHINOLONE AND -NAPHTHYRIDONE
IS8228A (en)	2006-01-11	New acetidine compounds
DK1682129T3 (en)	2007-06-11	N-thiazol-2-ylbenzamide derivatives
DK1706373T3 (en)	2010-01-18	Amidoacetonitrile derivatives
IS8292A (en)	2006-02-09	New compounds
IS8045A (en)	2005-09-26	Purin-6-one derivatives
FI20021817A0 (en)	2002-10-14	Cannula
UA6623S (en)	2002-11-15	SYRINGE
FI20030224A0 (en)	2003-02-13	New pharmaceutical uses
SE0301797D0 (en)	2003-06-19	New use V
SE0300106D0 (en)	2003-01-16	New use
SE0302332D0 (en)	2003-08-29	New use I
IS8301A (en)	2006-02-14	New Fusic Acid Derivatives